Business Wire - November 30, 2004
-- Animated Video Highlights Uniqueness of sPHirewall
-- HIV Drugs Could Be First Oral "Entry Inhibitors"
Samaritan Pharmaceuticals Inc., a developer of innovative drugs to target AIDS, Alzheimer's and cardiovascular disease, announced that today they will showcase their animated video of their HIV sPHirewall technology at the Wall Street Analyst Forum at the Roosevelt Hotel in NYC at 2 p.m. EST.
http://www.samaritanpharma.com/images/SamSphirewall.htm
The conference allows Samaritan to present their competitive advantages, to approximately 400 attending biotechnology analysts, and potential investors, via Vcall webcast.
http://www.vcall.com/conferences/conferences/WallStreetAnalyst Forum/113004/index.asp?Day=1 (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
About "sPHirewall technology"
Samaritan's "sPHirewall technology" was inspired by the Greek word "sfira" (heavy metallic), and "wall" (cell wall), to mean impassable cell wall.
The new trend for fighting HIV focuses on entry inhibitors, a new class of anti-HIV drugs that work by blocking the virus' ability to infect a cell.
So far, preclinical data for Samaritan's drugs, SP-01A, SP-10 and SP-03 have demonstrated that HIV is literally stopped from breaking through healthy cells, thereby halting HIV, extremely early on in the infectivity process.
Many believe the greater promise for entry inhibitors will be realized with small molecule drugs. Large molecule drugs must be taken by injection. Small molecules drugs, however, can be taken by mouth, avoiding the problems associated with injections.
Dr. Janet Greeson, CEO of Samaritan Pharmaceuticals, stated, "The promise of entry inhibitors, especially an easy-to-take oral drug with fewer side effects, could give Samaritan a unique competitive edge. If our HIV drugs continue on the same path and show promise, we could have human use within two or two and a half years."
Samaritan Pharmaceuticals: "A Cure Is Closer Than You Think."
Samaritan Pharmaceuticals is working to ensure a longer and better life, for patients suffering with AIDS, Alzheimer's, cancer and cardiovascular disease. Samaritan is an innovation-driven biopharmaceutical, with a clear focus on advancing innovative drugs through clinical development to become commercially valuable compounds.
Samaritan has in-licensed 12 innovations from Georgetown University and is concurrently advancing four drug programs: SP-01A (HIV) clinical trials; SP-10 (HIV) preIND status; SP-233 (Alzheimer's) preIND status; and SP-1000 (cardiovascular) animal studies; along with STTR NIH grants to develop a simple blood test to diagnose Alzheimer's and to study a novel series of neuroprotective compounds.
Samaritan's proprietary HIV drug SP-01A is the closest to commercialization. SP-01A is an easy-to-take, oral, "Entry Inhibitor" drug that works by blocking the HIV virus' ability to infect a cell. Encouraging data from its FDA Phase I/II trial suggests SP-01A as a promising drug for patients experiencing "drug resistance."
Visit our Web site at www.samaritanpharmaceuticals.com.
Disclaimer
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 14, 2004. The company undertakes no duty to update forward-looking statements.
MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=4774702
CONTACT: Samaritan Pharmaceuticals Inc., Las Vegas
Gene Boyle, 702-735-7001
Fax: 702-737-7016
E-mail: GeneBoyle@aol.com
SOURCE: Samaritan Pharmaceuticals Inc.
041130
BW041118
Copyright © 2004 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .